ID   WNK1_RAT                Reviewed;        2126 AA.
AC   Q9JIH7; Q3S2I2; Q6IFS7;
DT   02-FEB-2004, integrated into UniProtKB/Swiss-Prot.
DT   30-NOV-2010, sequence version 2.
DT   24-JUL-2024, entry version 191.
DE   RecName: Full=Serine/threonine-protein kinase WNK1 {ECO:0000305};
DE            EC=2.7.11.1 {ECO:0000269|PubMed:10828064, ECO:0000269|PubMed:12374799, ECO:0000269|PubMed:15350218, ECO:0000269|PubMed:16083423};
DE   AltName: Full=Protein kinase lysine-deficient 1 {ECO:0000312|RGD:621141};
DE   AltName: Full=Protein kinase with no lysine 1 {ECO:0000303|PubMed:10828064};
GN   Name=Wnk1 {ECO:0000303|PubMed:10828064, ECO:0000312|RGD:621141};
GN   Synonyms=Hsn2 {ECO:0000303|PubMed:15060842}, Prkwnk1;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116 {ECO:0000312|EMBL:AAF74258.1};
RN   [1] {ECO:0000305}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, CATALYTIC ACTIVITY,
RP   COFACTOR, ACTIVITY REGULATION, SUBCELLULAR LOCATION, CAUTION, ACTIVE SITE,
RP   AND MUTAGENESIS OF LYS-233; CYS-250; LYS-256; LYS-259 AND ASP-368.
RX   PubMed=10828064; DOI=10.1074/jbc.275.22.16795;
RA   Xu B.-E., English J.M., Wilsbacher J.L., Stippec S., Goldsmith E.J.,
RA   Cobb M.H.;
RT   "WNK1, a novel mammalian serine/threonine protein kinase lacking the
RT   catalytic lysine in subdomain II.";
RL   J. Biol. Chem. 275:16795-16801(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 4 AND 5), ALTERNATIVE SPLICING,
RP   FUNCTION (ISOFORM 5), AND SUBUNIT (ISOFORM 5).
RX   PubMed=16204408; DOI=10.1152/ajprenal.00280.2005;
RA   Subramanya A.R., Yang C.L., Zhu X., Ellison D.H.;
RT   "Dominant-negative regulation of WNK1 by its kidney-specific kinase-
RT   defective isoform.";
RL   Am. J. Physiol. 290:F619-F624(2006).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA] OF 312-2126.
RC   STRAIN=Brown Norway;
RX   PubMed=15057822; DOI=10.1038/nature02426;
RA   Gibbs R.A., Weinstock G.M., Metzker M.L., Muzny D.M., Sodergren E.J.,
RA   Scherer S., Scott G., Steffen D., Worley K.C., Burch P.E., Okwuonu G.,
RA   Hines S., Lewis L., Deramo C., Delgado O., Dugan-Rocha S., Miner G.,
RA   Morgan M., Hawes A., Gill R., Holt R.A., Adams M.D., Amanatides P.G.,
RA   Baden-Tillson H., Barnstead M., Chin S., Evans C.A., Ferriera S.,
RA   Fosler C., Glodek A., Gu Z., Jennings D., Kraft C.L., Nguyen T.,
RA   Pfannkoch C.M., Sitter C., Sutton G.G., Venter J.C., Woodage T., Smith D.,
RA   Lee H.-M., Gustafson E., Cahill P., Kana A., Doucette-Stamm L.,
RA   Weinstock K., Fechtel K., Weiss R.B., Dunn D.M., Green E.D.,
RA   Blakesley R.W., Bouffard G.G., De Jong P.J., Osoegawa K., Zhu B., Marra M.,
RA   Schein J., Bosdet I., Fjell C., Jones S., Krzywinski M., Mathewson C.,
RA   Siddiqui A., Wye N., McPherson J., Zhao S., Fraser C.M., Shetty J.,
RA   Shatsman S., Geer K., Chen Y., Abramzon S., Nierman W.C., Havlak P.H.,
RA   Chen R., Durbin K.J., Egan A., Ren Y., Song X.-Z., Li B., Liu Y., Qin X.,
RA   Cawley S., Cooney A.J., D'Souza L.M., Martin K., Wu J.Q.,
RA   Gonzalez-Garay M.L., Jackson A.R., Kalafus K.J., McLeod M.P.,
RA   Milosavljevic A., Virk D., Volkov A., Wheeler D.A., Zhang Z., Bailey J.A.,
RA   Eichler E.E., Tuzun E., Birney E., Mongin E., Ureta-Vidal A., Woodwark C.,
RA   Zdobnov E., Bork P., Suyama M., Torrents D., Alexandersson M., Trask B.J.,
RA   Young J.M., Huang H., Wang H., Xing H., Daniels S., Gietzen D., Schmidt J.,
RA   Stevens K., Vitt U., Wingrove J., Camara F., Mar Alba M., Abril J.F.,
RA   Guigo R., Smit A., Dubchak I., Rubin E.M., Couronne O., Poliakov A.,
RA   Huebner N., Ganten D., Goesele C., Hummel O., Kreitler T., Lee Y.-A.,
RA   Monti J., Schulz H., Zimdahl H., Himmelbauer H., Lehrach H., Jacob H.J.,
RA   Bromberg S., Gullings-Handley J., Jensen-Seaman M.I., Kwitek A.E.,
RA   Lazar J., Pasko D., Tonellato P.J., Twigger S., Ponting C.P., Duarte J.M.,
RA   Rice S., Goodstadt L., Beatson S.A., Emes R.D., Winter E.E., Webber C.,
RA   Brandt P., Nyakatura G., Adetobi M., Chiaromonte F., Elnitski L.,
RA   Eswara P., Hardison R.C., Hou M., Kolbe D., Makova K., Miller W.,
RA   Nekrutenko A., Riemer C., Schwartz S., Taylor J., Yang S., Zhang Y.,
RA   Lindpaintner K., Andrews T.D., Caccamo M., Clamp M., Clarke L., Curwen V.,
RA   Durbin R.M., Eyras E., Searle S.M., Cooper G.M., Batzoglou S., Brudno M.,
RA   Sidow A., Stone E.A., Payseur B.A., Bourque G., Lopez-Otin C., Puente X.S.,
RA   Chakrabarti K., Chatterji S., Dewey C., Pachter L., Bray N., Yap V.B.,
RA   Caspi A., Tesler G., Pevzner P.A., Haussler D., Roskin K.M., Baertsch R.,
RA   Clawson H., Furey T.S., Hinrichs A.S., Karolchik D., Kent W.J.,
RA   Rosenbloom K.R., Trumbower H., Weirauch M., Cooper D.N., Stenson P.D.,
RA   Ma B., Brent M., Arumugam M., Shteynberg D., Copley R.R., Taylor M.S.,
RA   Riethman H., Mudunuri U., Peterson J., Guyer M., Felsenfeld A., Old S.,
RA   Mockrin S., Collins F.S.;
RT   "Genome sequence of the Brown Norway rat yields insights into mammalian
RT   evolution.";
RL   Nature 428:493-521(2004).
RN   [4]
RP   IDENTIFICATION OF THE HSN2 EXON.
RX   PubMed=15060842; DOI=10.1086/420795;
RA   Lafreniere R.G., MacDonald M.L.E., Dube M.-P., MacFarlane J.,
RA   O'Driscoll M., Brais B., Meilleur S., Brinkman R.R., Dadivas O., Pape T.,
RA   Platon C., Radomski C., Risler J., Thompson J., Guerra-Escobio A.-M.,
RA   Davar G., Breakefield X.O., Pimstone S.N., Green R., Pryse-Phillips W.,
RA   Goldberg Y.P., Younghusband H.B., Hayden M.R., Sherrington R.,
RA   Rouleau G.A., Samuels M.E.;
RT   "Identification of a novel gene (HSN2) causing hereditary sensory and
RT   autonomic neuropathy type II through the study of Canadian genetic
RT   isolates.";
RL   Am. J. Hum. Genet. 74:1064-1073(2004).
RN   [5]
RP   FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, CAUTION, PHOSPHORYLATION
RP   AT SER-378 AND SER-382, REGION, AND MUTAGENESIS OF LYS-233; CYS-250;
RP   SER-378; SER-382; PHE-524 AND PHE-526.
RX   PubMed=12374799; DOI=10.1074/jbc.m207917200;
RA   Xu B.-E., Min X., Stippec S., Lee B.H., Goldsmith E.J., Cobb M.H.;
RT   "Regulation of WNK1 by an autoinhibitory domain and autophosphorylation.";
RL   J. Biol. Chem. 277:48456-48462(2002).
RN   [6]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=15350218; DOI=10.1016/j.molcel.2004.07.018;
RA   Lee B.H., Min X., Heise C.J., Xu B.E., Chen S., Shu H., Luby-Phelps K.,
RA   Goldsmith E.J., Cobb M.H.;
RT   "WNK1 phosphorylates synaptotagmin 2 and modulates its membrane binding.";
RL   Mol. Cell 15:741-751(2004).
RN   [7]
RP   FUNCTION, CATALYTIC ACTIVITY, ACTIVE SITE, AND MUTAGENESIS OF ASP-368.
RX   PubMed=16083423; DOI=10.1042/bj20051180;
RA   Vitari A.C., Deak M., Morrice N.A., Alessi D.R.;
RT   "The WNK1 and WNK4 protein kinases that are mutated in Gordon's
RT   hypertension syndrome phosphorylate and activate SPAK and OSR1 protein
RT   kinases.";
RL   Biochem. J. 391:17-24(2005).
RN   [8]
RP   FUNCTION, PHOSPHORYLATION AT THR-58, AND MUTAGENESIS OF THR-58.
RX   PubMed=16081417; DOI=10.1074/jbc.m505735200;
RA   Xu B.E., Stippec S., Lazrak A., Huang C.L., Cobb M.H.;
RT   "WNK1 activates SGK1 by a phosphatidylinositol 3-kinase-dependent and non-
RT   catalytic mechanism.";
RL   J. Biol. Chem. 280:34218-34223(2005).
RN   [9]
RP   FUNCTION, AND INTERACTION WITH SGK1.
RX   PubMed=16006511; DOI=10.1073/pnas.0504422102;
RA   Xu B.E., Stippec S., Chu P.Y., Lazrak A., Li X.J., Lee B.H., English J.M.,
RA   Ortega B., Huang C.L., Cobb M.H.;
RT   "WNK1 activates SGK1 to regulate the epithelial sodium channel.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:10315-10320(2005).
RN   [10]
RP   FUNCTION, AND INTERACTION WITH WNK3 AND WNK4.
RX   PubMed=17975670; DOI=10.1172/jci32033;
RA   Yang C.L., Zhu X., Ellison D.H.;
RT   "The thiazide-sensitive Na-Cl cotransporter is regulated by a WNK kinase
RT   signaling complex.";
RL   J. Clin. Invest. 117:3403-3411(2007).
RN   [11]
RP   FUNCTION, AND MUTAGENESIS OF LYS-233 AND SER-382.
RX   PubMed=16403833; DOI=10.1152/ajprenal.00391.2005;
RA   Fu Y., Subramanya A., Rozansky D., Cohen D.M.;
RT   "WNK kinases influence TRPV4 channel function and localization.";
RL   Am. J. Physiol. 290:F1305-F1314(2006).
RN   [12]
RP   FUNCTION.
RX   PubMed=17673510; DOI=10.1113/jphysiol.2007.135855;
RA   Dorwart M.R., Shcheynikov N., Wang Y., Stippec S., Muallem S.;
RT   "SLC26A9 is a Cl(-) channel regulated by the WNK kinases.";
RL   J. Physiol. (Lond.) 584:333-345(2007).
RN   [13]
RP   FUNCTION.
RX   PubMed=20525693; DOI=10.1074/jbc.m110.103432;
RA   Heise C.J., Xu B.E., Deaton S.L., Cha S.K., Cheng C.J., Earnest S.,
RA   Sengupta S., Juang Y.C., Stippec S., Xu Y., Zhao Y., Huang C.L., Cobb M.H.;
RT   "Serum and glucocorticoid-induced kinase (SGK) 1 and the epithelial sodium
RT   channel are regulated by multiple with no lysine (WNK) family members.";
RL   J. Biol. Chem. 285:25161-25167(2010).
RN   [14]
RP   FUNCTION, ACTIVITY REGULATION, PHOSPHORYLATION AT SER-382, AND MUTAGENESIS
RP   OF SER-382.
RX   PubMed=22544747; DOI=10.1074/jbc.m111.319418;
RA   Inoue K., Furukawa T., Kumada T., Yamada J., Wang T., Inoue R., Fukuda A.;
RT   "Taurine inhibits K+-Cl- cotransporter KCC2 to regulate embryonic
RT   Cl- homeostasis via with-no-lysine (WNK) protein kinase signaling
RT   pathway.";
RL   J. Biol. Chem. 287:20839-20850(2012).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-165; SER-172; SER-1773 AND
RP   SER-1776, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
RN   [16]
RP   ACTIVITY REGULATION.
RX   PubMed=28771350; DOI=10.1021/acs.jmedchem.7b00708;
RA   Yamada K., Levell J., Yoon T., Kohls D., Yowe D., Rigel D.F., Imase H.,
RA   Yuan J., Yasoshima K., DiPetrillo K., Monovich L., Xu L., Zhu M., Kato M.,
RA   Jain M., Idamakanti N., Taslimi P., Kawanami T., Argikar U.A.,
RA   Kunjathoor V., Xie X., Yagi Y.I., Iwaki Y., Robinson Z., Park H.M.;
RT   "Optimization of allosteric With-No-Lysine (WNK) kinase inhibitors and
RT   efficacy in rodent hypertension models.";
RL   J. Med. Chem. 60:7099-7107(2017).
RN   [17]
RP   ACTIVITY REGULATION.
RX   PubMed=33439774; DOI=10.1152/ajpcell.00456.2020;
RA   Pleinis J.M., Norrell L., Akella R., Humphreys J.M., He H., Sun Q.,
RA   Zhang F., Sosa-Pagan J., Morrison D.E., Schellinger J.N., Jackson L.K.,
RA   Goldsmith E.J., Rodan A.R.;
RT   "WNKs are potassium-sensitive kinases.";
RL   Am. J. Physiol. 320:C703-C721(2021).
RN   [18]
RP   FUNCTION, ACTIVITY REGULATION, SUBCELLULAR LOCATION, DOMAIN, AND
RP   MUTAGENESIS OF 568-LYS--VAL-599 AND 1820-LEU--GLN-1838.
RX   PubMed=36318922; DOI=10.1016/j.cell.2022.09.042;
RA   Boyd-Shiwarski C.R., Shiwarski D.J., Griffiths S.E., Beacham R.T.,
RA   Norrell L., Morrison D.E., Wang J., Mann J., Tennant W., Anderson E.N.,
RA   Franks J., Calderon M., Connolly K.A., Cheema M.U., Weaver C.J.,
RA   Nkashama L.J., Weckerly C.C., Querry K.E., Pandey U.B., Donnelly C.J.,
RA   Sun D., Rodan A.R., Subramanya A.R.;
RT   "WNK kinases sense molecular crowding and rescue cell volume via phase
RT   separation.";
RL   Cell 185:4488-4506(2022).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 194-483 OF MUTANT ALA-382.
RX   PubMed=15242606; DOI=10.1016/j.str.2004.04.014;
RA   Min X., Lee B.-H., Cobb M.H., Goldsmith E.J.;
RT   "Crystal structure of the kinase domain of WNK1, a kinase that causes a
RT   hereditary form of hypertension.";
RL   Structure 12:1303-1311(2004).
RN   [20]
RP   STRUCTURE BY NMR OF 480-572.
RX   PubMed=23376100; DOI=10.1016/j.jmb.2013.01.031;
RA   Moon T.M., Correa F., Kinch L.N., Piala A.T., Gardner K.H., Goldsmith E.J.;
RT   "Solution structure of the WNK1 autoinhibitory domain, a WNK-specific PF2
RT   domain.";
RL   J. Mol. Biol. 425:1245-1252(2013).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (3.50 ANGSTROMS) OF 194-480 OF MUTANT ALA-382 IN
RP   COMPLEX WITH BROMIDE, FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION,
RP   PHOSPHORYLATION AT SER-382, AND MUTAGENESIS OF LEU-299; LEU-369 AND
RP   LEU-371.
RX   PubMed=24803536; DOI=10.1126/scisignal.2005050;
RA   Piala A.T., Moon T.M., Akella R., He H., Cobb M.H., Goldsmith E.J.;
RT   "Chloride sensing by WNK1 involves inhibition of autophosphorylation.";
RL   Sci. Signal. 7:RA41-RA41(2014).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 194-483 OF MUTANT ALA-382 IN
RP   COMPLEX WITH INHIBITOR.
RX   PubMed=27595330; DOI=10.1038/nchembio.2168;
RA   Yamada K., Park H.M., Rigel D.F., DiPetrillo K., Whalen E.J., Anisowicz A.,
RA   Beil M., Berstler J., Brocklehurst C.E., Burdick D.A., Caplan S.L.,
RA   Capparelli M.P., Chen G., Chen W., Dale B., Deng L., Fu F., Hamamatsu N.,
RA   Harasaki K., Herr T., Hoffmann P., Hu Q.Y., Huang W.J., Idamakanti N.,
RA   Imase H., Iwaki Y., Jain M., Jeyaseelan J., Kato M., Kaushik V.K.,
RA   Kohls D., Kunjathoor V., LaSala D., Lee J., Liu J., Luo Y., Ma F., Mo R.,
RA   Mowbray S., Mogi M., Ossola F., Pandey P., Patel S.J., Raghavan S.,
RA   Salem B., Shanado Y.H., Trakshel G.M., Turner G., Wakai H., Wang C.,
RA   Weldon S., Wielicki J.B., Xie X., Xu L., Yagi Y.I., Yasoshima K., Yin J.,
RA   Yowe D., Zhang J.H., Zheng G., Monovich L.;
RT   "Small-molecule WNK inhibition regulates cardiovascular and renal
RT   function.";
RL   Nat. Chem. Biol. 12:896-898(2016).
CC   -!- FUNCTION: Serine/threonine-protein kinase component of the WNK1-
CC       SPAK/OSR1 kinase cascade, which acts as a key regulator of blood
CC       pressure and regulatory volume increase by promoting ion influx
CC       (PubMed:10828064, PubMed:12374799, PubMed:16083423, PubMed:17975670,
CC       PubMed:24803536, PubMed:36318922). WNK1 mediates regulatory volume
CC       increase in response to hyperosmotic stress by acting as a molecular
CC       crowding sensor, which senses cell shrinkage and mediates formation of
CC       a membraneless compartment by undergoing liquid-liquid phase separation
CC       (PubMed:36318922). The membraneless compartment concentrates WNK1 with
CC       its substrates, OXSR1/OSR1 and STK39/SPAK, promoting WNK1-dependent
CC       phosphorylation and activation of downstream kinases OXSR1/OSR1 and
CC       STK39/SPAK (PubMed:16083423, PubMed:36318922). Following activation,
CC       OXSR1/OSR1 and STK39/SPAK catalyze phosphorylation of ion
CC       cotransporters SLC12A1/NKCC2, SLC12A2/NKCC1, SLC12A5/KCC2 and
CC       SLC12A6/KCC3, regulating their activity (PubMed:22544747,
CC       PubMed:36318922). Phosphorylation of Na-K-Cl cotransporters
CC       SLC12A2/NKCC1 and SLC12A2/NKCC1 promote their activation and ion
CC       influx; simultaneously, phosphorylation of K-Cl cotransporters
CC       SLC12A5/KCC2 and SLC12A6/KCC3 inhibit their activity, blocking ion
CC       efflux (PubMed:36318922). Also acts as a regulator of angiogenesis in
CC       endothelial cells (By similarity). Also acts independently of the WNK1-
CC       SPAK/OSR1 kinase cascade by catalyzing phosphorylation of other
CC       substrates, such as SYT2, PCF11 and NEDD4L (PubMed:15350218,
CC       PubMed:20525693). Mediates phosphorylation of SYT2, regulating SYT2
CC       association with phospholipids and membrane-binding (PubMed:15350218).
CC       Regulates mRNA export in the nucleus by mediating phosphorylation of
CC       PCF11, thereby decreasing the association between PCF11 and POLR2A/RNA
CC       polymerase II and promoting mRNA export to the cytoplasm (By
CC       similarity). Acts as a negative regulator of autophagy (By similarity).
CC       Required for the abscission step during mitosis, independently of the
CC       WNK1-SPAK/OSR1 kinase cascade (By similarity). WNK1 may also play a
CC       role in actin cytoskeletal reorganization (By similarity). Also acts as
CC       a scaffold protein independently of its protein kinase activity:
CC       negatively regulates cell membrane localization of various transporters
CC       and channels, such as SLC4A4, SLC26A6, SLC26A9, TRPV4 and CFTR
CC       (PubMed:16403833, PubMed:17673510). Involved in the regulation of
CC       epithelial Na(+) channel (ENaC) by promoting activation of SGK1 in a
CC       kinase-independent manner (PubMed:16006511, PubMed:16081417). Probably
CC       activates SGK1 by acting as a scaffold protein that promotes the
CC       recruitment of SGK1 to the mTORC2 complex in response to chloride,
CC       leading to mTORC2-dependent phosphorylation and activation of SGK1 (By
CC       similarity). Acts as an assembly factor for the ER membrane protein
CC       complex independently of its protein kinase activity: associates with
CC       EMC2 in the cytoplasm via its amphipathic alpha-helix, and prevents
CC       EMC2 ubiquitination and subsequent degradation, thereby promoting EMC2
CC       stabilization (By similarity). {ECO:0000250|UniProtKB:P83741,
CC       ECO:0000250|UniProtKB:Q9H4A3, ECO:0000269|PubMed:10828064,
CC       ECO:0000269|PubMed:12374799, ECO:0000269|PubMed:15350218,
CC       ECO:0000269|PubMed:16006511, ECO:0000269|PubMed:16081417,
CC       ECO:0000269|PubMed:16083423, ECO:0000269|PubMed:16403833,
CC       ECO:0000269|PubMed:17673510, ECO:0000269|PubMed:17975670,
CC       ECO:0000269|PubMed:20525693, ECO:0000269|PubMed:22544747,
CC       ECO:0000269|PubMed:24803536, ECO:0000269|PubMed:36318922}.
CC   -!- FUNCTION: [Isoform 5]: Kinase-defective isoform specifically expressed
CC       in kidney, which acts as a dominant-negative regulator of the longer
CC       isoform 1 (PubMed:16204408). Does not directly inhibit WNK4 and has no
CC       direct effect on sodium and chloride ion transport (PubMed:16204408).
CC       Down-regulates sodium-chloride cotransporter activity indirectly by
CC       inhibiting isoform 1, it associates with isoform 1 and attenuates its
CC       kinase activity (PubMed:16204408). In kidney, may play an important
CC       role regulating sodium and potassium balance (PubMed:16204408).
CC       {ECO:0000269|PubMed:16204408}.
CC   -!- FUNCTION: [Isoform 4]: Kinase-defective isoform produced by alternative
CC       promoter usage and alternative splicing. {ECO:0000269|PubMed:16204408}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC         Evidence={ECO:0000269|PubMed:10828064, ECO:0000269|PubMed:12374799,
CC         ECO:0000269|PubMed:24803536};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1; Evidence={ECO:0000269|PubMed:10828064,
CC         ECO:0000269|PubMed:12374799, ECO:0000269|PubMed:15350218,
CC         ECO:0000269|PubMed:16083423, ECO:0000269|PubMed:24803536};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:10828064, ECO:0000269|PubMed:16083423};
CC   -!- ACTIVITY REGULATION: Activated in response to hyperosmotic stress: cell
CC       shrinkage promotes formation of a membraneless compartment that
CC       concentrates WNK1 with its substrates, OXSR1/OSR1 and STK39/SPAK
CC       (PubMed:10828064, PubMed:36318922). Activation requires
CC       autophosphorylation of Ser-382 and, to a lower extent, Ser-378
CC       (PubMed:12374799, PubMed:22544747, PubMed:24803536).
CC       Autophosphorylation and subsequent activation is inhibited by increases
CC       in intracellular ionic strength: Cl(-) potently inhibits WNK1 kinase
CC       activity via direct binding (PubMed:24803536). Also inhibited by K(+)
CC       ions (PubMed:33439774). Inhibited by Compound 12 ((5-Chloro-2-(2-
CC       ((methyl-d3)amino)thiazol-4-yl)- pyridin-4-yl)(4-(4-
CC       chlorobenzyl)piperazin-1-yl)methanone) (PubMed:28771350).
CC       {ECO:0000269|PubMed:10828064, ECO:0000269|PubMed:12374799,
CC       ECO:0000269|PubMed:22544747, ECO:0000269|PubMed:24803536,
CC       ECO:0000269|PubMed:28771350, ECO:0000269|PubMed:33439774,
CC       ECO:0000269|PubMed:36318922}.
CC   -!- SUBUNIT: Interacts with WNK3 (PubMed:17975670). Interacts with WNK4;
CC       inhibiting the activity of WNK4 (PubMed:17975670). Interacts with SGK1;
CC       promoting its activation (PubMed:16006511). Associates with the mTORC2
CC       complex (By similarity). Interacts with UVRAG (By similarity).
CC       Interacts (via amphipathic alpha-helix region) with EMC2; promoting the
CC       ER membrane protein complex assembly (By similarity).
CC       {ECO:0000250|UniProtKB:Q9H4A3, ECO:0000269|PubMed:16006511,
CC       ECO:0000269|PubMed:17975670}.
CC   -!- SUBUNIT: [Isoform 5]: Interacts with isoform 1; inhibiting isoform 1
CC       activity. {ECO:0000269|PubMed:16204408}.
CC   -!- INTERACTION:
CC       Q9JIH7; P29101: Syt2; NbExp=9; IntAct=EBI-457953, EBI-458017;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:10828064,
CC       ECO:0000269|PubMed:36318922}. Nucleus {ECO:0000250|UniProtKB:Q9H4A3}.
CC       Cytoplasm, cytoskeleton, spindle {ECO:0000250|UniProtKB:Q9H4A3}.
CC       Note=Mediates formation and localizes to cytoplasmic membraneless
CC       compartment in response to hyperosmotic stress (PubMed:36318922). Also
CC       localizes to the nucleus (By similarity). Localizes to the mitotic
CC       spindle during mitosis (By similarity). {ECO:0000250|UniProtKB:Q9H4A3,
CC       ECO:0000269|PubMed:36318922}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1;
CC         IsoId=Q9JIH7-1; Sequence=Displayed;
CC       Name=2; Synonyms=Brain and spinal cord variant;
CC         IsoId=Q9JIH7-3; Sequence=VSP_040279;
CC       Name=3; Synonyms=Dorsal root ganglia and sciatic nerve variant, DRG and
CC       sciatic nerve variant;
CC         IsoId=Q9JIH7-2; Sequence=VSP_040278, VSP_040280;
CC       Name=4; Synonyms=KS-WNK1-long, Kidney-Specific long form
CC       {ECO:0000303|PubMed:16204408};
CC         IsoId=Q9JIH7-4; Sequence=VSP_058594, VSP_058596;
CC       Name=5; Synonyms=KS-WNK1-short, Kidney-Specific short form
CC       {ECO:0000303|PubMed:16204408};
CC         IsoId=Q9JIH7-5; Sequence=VSP_058595, VSP_058596;
CC   -!- DOMAIN: The RFXV motifs mediate recognition with downstream kinases
CC       OXSR1/OSR1 and STK39/SPAK. {ECO:0000250|UniProtKB:Q9H4A3}.
CC   -!- DOMAIN: Disordered regions undergo liquid-liquid phase separation
CC       (LLPS) for the formation of a cytoplasmic membraneless compartment that
CC       concentrates WNK1 with its substrates, OXSR1/OSR1 and STK39/SPAK.
CC       {ECO:0000269|PubMed:36318922}.
CC   -!- PTM: Autophosphorylated at Ser-378 and Ser-382, promoting its activity
CC       (PubMed:12374799, PubMed:22544747, PubMed:24803536).
CC       Autophosphorylation at Ser-382 is inhibited by intracellular calcium
CC       (PubMed:24803536). Phosphorylation at Thr-58 increases ability to
CC       activate SGK1 (PubMed:16081417). {ECO:0000269|PubMed:12374799,
CC       ECO:0000269|PubMed:16081417, ECO:0000269|PubMed:22544747,
CC       ECO:0000269|PubMed:24803536}.
CC   -!- PTM: Ubiquitinated by the BCR(KLHL3) complex, leading to its
CC       degradation (By similarity). Also ubiquitinated by the BCR(KLHL2)
CC       complex (By similarity). {ECO:0000250|UniProtKB:Q9H4A3}.
CC   -!- PTM: May be O-glycosylated. {ECO:0000250|UniProtKB:Q9H4A3}.
CC   -!- MISCELLANEOUS: [Isoform 2]: This isoform which includes the HSN2 exon
CC       has been identified in human and mouse. The sequence shown here is the
CC       result of gene prediction. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 3]: This isoform which includes the HSN2 exon
CC       has been identified in human and mouse. The sequence shown here is the
CC       result of gene prediction. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein
CC       kinase family. WNK subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- CAUTION: Was named WNK/'with no lysine(K)' because key residues for
CC       catalysis, including the lysine involved in ATP binding, are either not
CC       conserved or differ compared to the residues described in other kinase
CC       family proteins. {ECO:0000305|PubMed:10828064,
CC       ECO:0000305|PubMed:12374799}.
CC   -!- CAUTION: HSN2 was originally thought to be an intronless gene lying
CC       within a WNK1 gene intron. It has been shown to be an alternative exon
CC       of the WNK1 gene in other mammalian species, including human and mouse.
CC       Isoforms bearing this exon (isoform 2 and isoform 3 in this entry) are
CC       specifically expressed in the nervous system in these species. system.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=DAA04492.1; Type=Erroneous gene model prediction; Note=Includes 3' and 3' intronic sequences.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF227741; AAF74258.1; -; mRNA.
DR   EMBL; DQ177457; ABA02202.1; -; mRNA.
DR   EMBL; AC106348; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BK004106; DAA04492.1; ALT_SEQ; Genomic_DNA.
DR   RefSeq; NP_001002823.2; NM_001002823.2. [Q9JIH7-2]
DR   RefSeq; NP_001186024.1; NM_001199095.1. [Q9JIH7-3]
DR   RefSeq; NP_446246.2; NM_053794.2. [Q9JIH7-1]
DR   PDB; 2LRU; NMR; -; A=480-572.
DR   PDB; 4Q2A; X-ray; 3.50 A; A=194-480.
DR   PDB; 5DRB; X-ray; 1.65 A; A=194-483.
DR   PDB; 5W7T; X-ray; 2.01 A; A/B=210-482.
DR   PDB; 6CN9; X-ray; 1.80 A; A/B=194-483.
DR   PDB; 6OL2; X-ray; 2.10 A; A=194-483.
DR   PDB; 7UOS; X-ray; 2.90 A; A=194-483.
DR   PDBsum; 2LRU; -.
DR   PDBsum; 4Q2A; -.
DR   PDBsum; 5DRB; -.
DR   PDBsum; 5W7T; -.
DR   PDBsum; 6CN9; -.
DR   PDBsum; 6OL2; -.
DR   PDBsum; 7UOS; -.
DR   AlphaFoldDB; Q9JIH7; -.
DR   BMRB; Q9JIH7; -.
DR   SMR; Q9JIH7; -.
DR   IntAct; Q9JIH7; 6.
DR   STRING; 10116.ENSRNOP00000013355; -.
DR   CarbonylDB; Q9JIH7; -.
DR   GlyGen; Q9JIH7; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q9JIH7; -.
DR   PhosphoSitePlus; Q9JIH7; -.
DR   jPOST; Q9JIH7; -.
DR   ABCD; Q9JIH7; 1 sequenced antibody.
DR   Ensembl; ENSRNOT00000013355.7; ENSRNOP00000013355.5; ENSRNOG00000009956.9. [Q9JIH7-2]
DR   Ensembl; ENSRNOT00000013621.7; ENSRNOP00000013622.5; ENSRNOG00000009956.9. [Q9JIH7-3]
DR   GeneID; 116477; -.
DR   KEGG; rno:116477; -.
DR   UCSC; RGD:621141; rat. [Q9JIH7-1]
DR   AGR; RGD:621141; -.
DR   CTD; 65125; -.
DR   RGD; 621141; Wnk1.
DR   VEuPathDB; HostDB:ENSRNOG00000009956; -.
DR   eggNOG; KOG0584; Eukaryota.
DR   GeneTree; ENSGT00940000155474; -.
DR   HOGENOM; CLU_000550_0_1_1; -.
DR   InParanoid; Q9JIH7; -.
DR   OrthoDB; 5478852at2759; -.
DR   PhylomeDB; Q9JIH7; -.
DR   EvolutionaryTrace; Q9JIH7; -.
DR   PRO; PR:Q9JIH7; -.
DR   Proteomes; UP000002494; Chromosome 4.
DR   Bgee; ENSRNOG00000009956; Expressed in Ammon's horn and 20 other cell types or tissues.
DR   ExpressionAtlas; Q9JIH7; baseline and differential.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0098982; C:GABA-ergic synapse; IDA:SynGO.
DR   GO; GO:0043232; C:intracellular non-membrane-bounded organelle; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0072686; C:mitotic spindle; ISS:UniProtKB.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0032991; C:protein-containing complex; ISO:RGD.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0000287; F:magnesium ion binding; IMP:RGD.
DR   GO; GO:0140693; F:molecular condensate scaffold activity; IDA:UniProtKB.
DR   GO; GO:0019902; F:phosphatase binding; ISS:UniProtKB.
DR   GO; GO:0019870; F:potassium channel inhibitor activity; IDA:RGD.
DR   GO; GO:0030295; F:protein kinase activator activity; ISO:RGD.
DR   GO; GO:0004672; F:protein kinase activity; ISO:RGD.
DR   GO; GO:0019901; F:protein kinase binding; IPI:RGD.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0030291; F:protein serine/threonine kinase inhibitor activity; IDA:RGD.
DR   GO; GO:0006884; P:cell volume homeostasis; IDA:UniProtKB.
DR   GO; GO:0071474; P:cellular hyperosmotic response; IDA:UniProtKB.
DR   GO; GO:0071277; P:cellular response to calcium ion; IDA:UniProtKB.
DR   GO; GO:1990869; P:cellular response to chemokine; ISO:RGD.
DR   GO; GO:0038116; P:chemokine (C-C motif) ligand 21 signaling pathway; ISO:RGD.
DR   GO; GO:0007507; P:heart development; ISO:RGD.
DR   GO; GO:0030644; P:intracellular chloride ion homeostasis; ISO:RGD.
DR   GO; GO:0035556; P:intracellular signal transduction; IDA:UniProtKB.
DR   GO; GO:0097022; P:lymphocyte migration into lymph node; ISO:RGD.
DR   GO; GO:0050804; P:modulation of chemical synaptic transmission; IDA:SynGO.
DR   GO; GO:0055080; P:monoatomic cation homeostasis; ISS:UniProtKB.
DR   GO; GO:0050801; P:monoatomic ion homeostasis; IBA:GO_Central.
DR   GO; GO:0006811; P:monoatomic ion transport; ISS:UniProtKB.
DR   GO; GO:0010507; P:negative regulation of autophagy; ISS:UniProtKB.
DR   GO; GO:0033633; P:negative regulation of cell-cell adhesion mediated by integrin; ISO:RGD.
DR   GO; GO:0034115; P:negative regulation of heterotypic cell-cell adhesion; ISO:RGD.
DR   GO; GO:1903038; P:negative regulation of leukocyte cell-cell adhesion; ISO:RGD.
DR   GO; GO:0090188; P:negative regulation of pancreatic juice secretion; ISO:RGD.
DR   GO; GO:1903077; P:negative regulation of protein localization to plasma membrane; IDA:UniProtKB.
DR   GO; GO:0031397; P:negative regulation of protein ubiquitination; ISS:UniProtKB.
DR   GO; GO:0010766; P:negative regulation of sodium ion transport; IDA:UniProtKB.
DR   GO; GO:0140694; P:non-membrane-bounded organelle assembly; ISS:UniProtKB.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; ISS:UniProtKB.
DR   GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; ISO:RGD.
DR   GO; GO:1903490; P:positive regulation of mitotic cytokinesis; ISS:UniProtKB.
DR   GO; GO:1903288; P:positive regulation of potassium ion import across plasma membrane; IBA:GO_Central.
DR   GO; GO:0003084; P:positive regulation of systemic arterial blood pressure; ISO:RGD.
DR   GO; GO:0010820; P:positive regulation of T cell chemotaxis; ISO:RGD.
DR   GO; GO:1904595; P:positive regulation of termination of RNA polymerase II transcription; ISS:UniProtKB.
DR   GO; GO:0055075; P:potassium ion homeostasis; ISO:RGD.
DR   GO; GO:0045050; P:protein insertion into ER membrane by stop-transfer membrane-anchor sequence; ISS:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0008217; P:regulation of blood pressure; ISO:RGD.
DR   GO; GO:1904062; P:regulation of monoatomic cation transmembrane transport; ISO:RGD.
DR   GO; GO:0010793; P:regulation of mRNA export from nucleus; ISS:UniProtKB.
DR   GO; GO:1902305; P:regulation of sodium ion transmembrane transport; ISO:RGD.
DR   GO; GO:0002028; P:regulation of sodium ion transport; IDA:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; ISO:RGD.
DR   GO; GO:0035725; P:sodium ion transmembrane transport; ISO:RGD.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; ISO:RGD.
DR   CDD; cd14030; STKc_WNK1; 1.
DR   Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR024678; Kinase_OSR1/WNK_CCT.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   InterPro; IPR050588; WNK_Ser-Thr_kinase.
DR   PANTHER; PTHR13902; SERINE/THREONINE-PROTEIN KINASE WNK WITH NO LYSINE -RELATED; 1.
DR   PANTHER; PTHR13902:SF46; SERINE_THREONINE-PROTEIN KINASE WNK1; 1.
DR   Pfam; PF12202; OSR1_C; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; Protein kinase-like (PK-like); 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Chloride; Cytoplasm;
KW   Cytoskeleton; Kinase; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Reference proteome; Serine/threonine-protein kinase; Transferase;
KW   Ubl conjugation.
FT   CHAIN           1..2126
FT                   /note="Serine/threonine-protein kinase WNK1"
FT                   /id="PRO_0000086821"
FT   DOMAIN          221..479
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          1..80
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          93..202
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          488..555
FT                   /note="Autoinhibitory domain"
FT                   /evidence="ECO:0000269|PubMed:12374799"
FT   REGION          573..865
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          629..639
FT                   /note="Interaction with KLHL3"
FT                   /evidence="ECO:0000250|UniProtKB:Q96J92"
FT   REGION          1474..1507
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1557..1595
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1610..1695
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1709..1783
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1856..1940
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1952..1990
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1985..2005
FT                   /note="Amphipathic alpha-helix"
FT                   /evidence="ECO:0000250|UniProtKB:Q9H4A3"
FT   REGION          2076..2097
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           1003..1006
FT                   /note="RFXV motif 1"
FT                   /evidence="ECO:0000250|UniProtKB:Q9H4A3"
FT   MOTIF           1604..1607
FT                   /note="RFXV motif 2"
FT                   /evidence="ECO:0000250|UniProtKB:Q9H4A3"
FT   MOTIF           1690..1693
FT                   /note="RFXV motif 3"
FT                   /evidence="ECO:0000250|UniProtKB:Q9H4A3"
FT   MOTIF           1702..1705
FT                   /note="RFXV motif 4"
FT                   /evidence="ECO:0000250|UniProtKB:Q9H4A3"
FT   COMPBIAS        47..63
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        99..113
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        123..166
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        178..194
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        573..589
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        590..630
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        637..838
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        842..862
FT                   /note="Basic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1474..1503
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1563..1593
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1611..1630
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1631..1654
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1676..1695
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1709..1723
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1877..1940
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1952..1988
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        2083..2097
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        368
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000305|PubMed:10828064,
FT                   ECO:0000305|PubMed:16083423"
FT   BINDING         231
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:Q9H4A3"
FT   BINDING         283
FT                   /ligand="chloride"
FT                   /ligand_id="ChEBI:CHEBI:17996"
FT                   /evidence="ECO:0000305|PubMed:24803536,
FT                   ECO:0007744|PDB:4Q2A"
FT   BINDING         299
FT                   /ligand="chloride"
FT                   /ligand_id="ChEBI:CHEBI:17996"
FT                   /evidence="ECO:0000305|PubMed:24803536,
FT                   ECO:0007744|PDB:4Q2A"
FT   BINDING         301..304
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:Q9H4A3"
FT   BINDING         351
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:Q9H4A3"
FT   BINDING         369
FT                   /ligand="chloride"
FT                   /ligand_id="ChEBI:CHEBI:17996"
FT                   /evidence="ECO:0000305|PubMed:24803536,
FT                   ECO:0007744|PDB:4Q2A"
FT   BINDING         371
FT                   /ligand="chloride"
FT                   /ligand_id="ChEBI:CHEBI:17996"
FT                   /evidence="ECO:0000305|PubMed:24803536,
FT                   ECO:0007744|PDB:4Q2A"
FT   MOD_RES         17
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9H4A3"
FT   MOD_RES         58
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:16081417"
FT   MOD_RES         165
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         172
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         378
FT                   /note="Phosphoserine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:12374799"
FT   MOD_RES         382
FT                   /note="Phosphoserine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:12374799,
FT                   ECO:0000269|PubMed:22544747"
FT   MOD_RES         1007
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9H4A3"
FT   MOD_RES         1723
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9H4A3"
FT   MOD_RES         1755
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9H4A3"
FT   MOD_RES         1756
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9H4A3"
FT   MOD_RES         1771
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9H4A3"
FT   MOD_RES         1773
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         1776
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         1865
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9H4A3"
FT   MOD_RES         2014
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P83741"
FT   MOD_RES         2030
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P83741"
FT   MOD_RES         2114
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9H4A3"
FT   MOD_RES         2116
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9H4A3"
FT   VAR_SEQ         1..437
FT                   /note="MSDGTAEKQSGTPGFLSPPAPVPKNGSSSDSSVGEKLGAAVADSGIGRTEEY
FT                   RRRRHTMDKDSRGAAATTTPTEHRFFRRSVICDSNATALELPGLPLSIPQPSVPAVVPQ
FT                   SAPPEPHREETLTATVASQVSQQPSAAASPGEQAVVGSATATVPSSTSKDRPVSQPSLV
FT                   GSKEEPPPSRSGSGSGGASAKEPQEERNQQQDDIEELETKAVGMSNDGRFLKFDIEIGR
FT                   GSFKTVYKGLDTETTVEVAWCELQDRKLTKSERQRFKEEAEMLKGLQHPNIVRFYDSWE
FT                   STVKGKKCIVLVTELMTSGTLKTYLKRFKVMKIKVLRSWCRQILKGLQFLHTRTPPIIH
FT                   RDLKCDNIFITGPTGSVKIGDLGLATLKRASFAKSVIGTPEFMAPEMYEEKYDESVDVY
FT                   AFGMCMLEMATSEYPYSECQNAAQIYRRVTS -> MVVCISIYFPPSFFLNSIKSVLPF
FT                   LMDFLKKDFCSVFVIVNSHCCCCSQKDCINE (in isoform 4)"
FT                   /id="VSP_058594"
FT   VAR_SEQ         1..437
FT                   /note="MSDGTAEKQSGTPGFLSPPAPVPKNGSSSDSSVGEKLGAAVADSGIGRTEEY
FT                   RRRRHTMDKDSRGAAATTTPTEHRFFRRSVICDSNATALELPGLPLSIPQPSVPAVVPQ
FT                   SAPPEPHREETLTATVASQVSQQPSAAASPGEQAVVGSATATVPSSTSKDRPVSQPSLV
FT                   GSKEEPPPSRSGSGSGGASAKEPQEERNQQQDDIEELETKAVGMSNDGRFLKFDIEIGR
FT                   GSFKTVYKGLDTETTVEVAWCELQDRKLTKSERQRFKEEAEMLKGLQHPNIVRFYDSWE
FT                   STVKGKKCIVLVTELMTSGTLKTYLKRFKVMKIKVLRSWCRQILKGLQFLHTRTPPIIH
FT                   RDLKCDNIFITGPTGSVKIGDLGLATLKRASFAKSVIGTPEFMAPEMYEEKYDESVDVY
FT                   AFGMCMLEMATSEYPYSECQNAAQIYRRVTS -> MDFLKKDFCSVFVIVNSHCCCCSQ
FT                   KDCINE (in isoform 5)"
FT                   /id="VSP_058595"
FT   VAR_SEQ         543..2126
FT                   /note="Missing (in isoform 4 and isoform 5)"
FT                   /id="VSP_058596"
FT   VAR_SEQ         714
FT                   /note="M -> MPRRGRSMSVCVPHLSAVPSLSRISPSAPSTPPPVLSAPLCPSLLRS
FT                   APEETFAEKLSKALESVLPMHSASQRKHRRSSLPSLFVTTPQSVAHPCGGTPTYPESQI
FT                   FFPTIHERPVSFSPPPTCPPKVAISQRRKSTSFLEAQTRHFQPLLRTVGQNHLPPGGSP
FT                   TNWTPEAIVMLGTTANRVNRELCEMQVQPVFETTQIYSDYRPGLVLAEEAHYFIPQETV
FT                   YLAGVHYQAHAAGQYEGISYNSPVLSSPMKQITEQKPVPGCPASSSVFEFPSGQAFLVG
FT                   HLQNLRLDSGPSPASPLSSISAPNSTDATHLKFHPVFVPHSAPAVLTHSNENRSNCVFE
FT                   FHAQTPSSSSGEGGGILPQRVYRNRQVAVDSSQEELSPQSVGLHCHLQPVTEEQRNNHT
FT                   PELTISVVEPMGQNWPVGSPEYSSDSSQITSSDISDFQSPPPTGGTAAPFGSDVSLPYI
FT                   RLPQTVLQESPLFFCFPQGTTSQQVLSASYSSGGSALHPQ (in isoform 2)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_040279"
FT   VAR_SEQ         714
FT                   /note="M -> MPQSVAHPCGGTPTYPESQIFFPTIHERPVSFSPPPTCPPKVAISQR
FT                   RKSTSFLEAQTRHFQPLLRTVGQNHLPPGGSPTNWTPEAIVMLGTTANRVNRELCEMQV
FT                   QPVFETTQIYSDYRPGLVLAEEAHYFIPQETVYLAGVHYQAHAAGQYEGISYNSPVLSS
FT                   PMKQITEQKPVPGCPASSSVFEFPSGQAFLVGHLQNLRLDSGPSPASPLSSISAPNSTD
FT                   ATHLKFHPVFVPHSAPAVLTHSNENRSNCVFEFHAQTPSSSSGEGGGILPQRVYRNRQV
FT                   AVDSSQEELSPQSVGLHCHLQPVTEEQRNNHTPELTISVVEPMGQNWPVGSPEYSSDSS
FT                   QITSSDISDFQSPPPTGGTAAPFGSDVSLPYIRLPQTVLQESPLFFCFPQGTTSQQVLS
FT                   ASYSSGGSALHPQ (in isoform 3)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_040278"
FT   VAR_SEQ         782
FT                   /note="Q -> QGFPSRLPPQYPGDSNIAPSSNVASVCIHSTVLAPPPMPTEALATQG
FT                   YFPTVVQPYVESTPLVPMGSVGGQVQVSQPAVSLSQQPPTTSSQQAVLE (in
FT                   isoform 3)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_040280"
FT   MUTAGEN         58
FT                   /note="T->A: Decreased ability to activate SGK1."
FT                   /evidence="ECO:0000269|PubMed:16081417"
FT   MUTAGEN         233
FT                   /note="K->G: Loss of kinase activity; when associated with
FT                   K-250. Abolished serine/threonine-protein kinase activity
FT                   without affecting ability to regulate localization of
FT                   TRPV4."
FT                   /evidence="ECO:0000269|PubMed:10828064,
FT                   ECO:0000269|PubMed:12374799, ECO:0000269|PubMed:16403833"
FT   MUTAGEN         233
FT                   /note="K->M: Loss of kinase activity."
FT                   /evidence="ECO:0000269|PubMed:10828064,
FT                   ECO:0000269|PubMed:12374799"
FT   MUTAGEN         250
FT                   /note="C->A: No effect on kinase activity."
FT                   /evidence="ECO:0000269|PubMed:10828064,
FT                   ECO:0000269|PubMed:12374799"
FT   MUTAGEN         250
FT                   /note="C->K: Reduced kinase activity. Loss of kinase
FT                   activity; when associated with G-233."
FT                   /evidence="ECO:0000269|PubMed:10828064,
FT                   ECO:0000269|PubMed:12374799"
FT   MUTAGEN         256
FT                   /note="K->M: No effect on kinase activity."
FT                   /evidence="ECO:0000269|PubMed:10828064"
FT   MUTAGEN         259
FT                   /note="K->M: No effect on kinase activity."
FT                   /evidence="ECO:0000269|PubMed:10828064"
FT   MUTAGEN         299
FT                   /note="L->F: Decreased inhibition by Cl(-) ions."
FT                   /evidence="ECO:0000269|PubMed:24803536"
FT   MUTAGEN         368
FT                   /note="D->A: Loss of kinase activity."
FT                   /evidence="ECO:0000269|PubMed:10828064,
FT                   ECO:0000269|PubMed:16083423"
FT   MUTAGEN         369
FT                   /note="L->F: Decreased inhibition by Cl(-) ions."
FT                   /evidence="ECO:0000269|PubMed:24803536"
FT   MUTAGEN         371
FT                   /note="L->F: Decreased inhibition by Cl(-) ions."
FT                   /evidence="ECO:0000269|PubMed:24803536"
FT   MUTAGEN         378
FT                   /note="S->A: Reduced kinase activity."
FT                   /evidence="ECO:0000269|PubMed:12374799"
FT   MUTAGEN         378
FT                   /note="S->D: Increased kinase activity."
FT                   /evidence="ECO:0000269|PubMed:12374799"
FT   MUTAGEN         382
FT                   /note="S->A: Impaired autophosphorylation and subsequent
FT                   activation. Does not affect ability to regulate
FT                   localization of TRPV4."
FT                   /evidence="ECO:0000269|PubMed:12374799,
FT                   ECO:0000269|PubMed:16403833"
FT   MUTAGEN         382
FT                   /note="S->D,E: Mimics phosphorylation; Increased kinase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:12374799,
FT                   ECO:0000269|PubMed:22544747"
FT   MUTAGEN         524
FT                   /note="F->A: Reduced ability of autoinhibitory domain to
FT                   regulate kinase activity."
FT                   /evidence="ECO:0000269|PubMed:12374799"
FT   MUTAGEN         526
FT                   /note="F->A: Reduced ability of autoinhibitory domain to
FT                   regulate kinase activity."
FT                   /evidence="ECO:0000269|PubMed:12374799"
FT   MUTAGEN         568..599
FT                   /note="KREQRQLVREEQEKRKQEESSFKQQNEQQASV->PREQRQLPREEQEKRKQE
FT                   ESSPKQPNEQPASP: In MidCC(mut); decreased ability to undergo
FT                   liquid-liquid phase separation (LLPS) for the formation of
FT                   a cytoplasmic membraneless compartment."
FT                   /evidence="ECO:0000269|PubMed:36318922"
FT   MUTAGEN         1820..1838
FT                   /note="LRRLREKHLKEIQDLQSRQ->PRRLREKPLKEPQDPQSRP: In
FT                   CC(mut); decreased ability to undergo liquid-liquid phase
FT                   separation (LLPS) for the formation of a cytoplasmic
FT                   membraneless compartment."
FT                   /evidence="ECO:0000269|PubMed:36318922"
FT   CONFLICT        1179
FT                   /note="S -> F (in Ref. 1; AAF74258)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1950
FT                   /note="V -> I (in Ref. 1; AAF74258)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        2120
FT                   /note="G -> S (in Ref. 1; AAF74258)"
FT                   /evidence="ECO:0000305"
FT   STRAND          211..214
FT                   /evidence="ECO:0007829|PDB:5DRB"
FT   STRAND          220..229
FT                   /evidence="ECO:0007829|PDB:5DRB"
FT   STRAND          231..240
FT                   /evidence="ECO:0007829|PDB:5DRB"
FT   TURN            241..243
FT                   /evidence="ECO:0007829|PDB:5DRB"
FT   STRAND          246..252
FT                   /evidence="ECO:0007829|PDB:5DRB"
FT   HELIX           254..256
FT                   /evidence="ECO:0007829|PDB:6CN9"
FT   HELIX           259..273
FT                   /evidence="ECO:0007829|PDB:5DRB"
FT   STRAND          283..291
FT                   /evidence="ECO:0007829|PDB:5DRB"
FT   STRAND          294..302
FT                   /evidence="ECO:0007829|PDB:5DRB"
FT   HELIX           309..316
FT                   /evidence="ECO:0007829|PDB:5DRB"
FT   HELIX           321..339
FT                   /evidence="ECO:0007829|PDB:5DRB"
FT   STRAND          341..343
FT                   /evidence="ECO:0007829|PDB:5DRB"
FT   STRAND          354..359
FT                   /evidence="ECO:0007829|PDB:5DRB"
FT   STRAND          364..366
FT                   /evidence="ECO:0007829|PDB:5DRB"
FT   HELIX           371..374
FT                   /evidence="ECO:0007829|PDB:5DRB"
FT   STRAND          377..379
FT                   /evidence="ECO:0007829|PDB:5DRB"
FT   HELIX           387..389
FT                   /evidence="ECO:0007829|PDB:5W7T"
FT   HELIX           392..396
FT                   /evidence="ECO:0007829|PDB:5DRB"
FT   HELIX           402..417
FT                   /evidence="ECO:0007829|PDB:5DRB"
FT   TURN            421..424
FT                   /evidence="ECO:0007829|PDB:5DRB"
FT   HELIX           428..435
FT                   /evidence="ECO:0007829|PDB:5DRB"
FT   TURN            436..438
FT                   /evidence="ECO:0007829|PDB:5DRB"
FT   HELIX           442..446
FT                   /evidence="ECO:0007829|PDB:5DRB"
FT   HELIX           450..459
FT                   /evidence="ECO:0007829|PDB:5DRB"
FT   HELIX           464..466
FT                   /evidence="ECO:0007829|PDB:5DRB"
FT   HELIX           470..474
FT                   /evidence="ECO:0007829|PDB:5DRB"
FT   HELIX           477..479
FT                   /evidence="ECO:0007829|PDB:5DRB"
FT   STRAND          484..491
FT                   /evidence="ECO:0007829|PDB:2LRU"
FT   STRAND          498..507
FT                   /evidence="ECO:0007829|PDB:2LRU"
FT   STRAND          511..515
FT                   /evidence="ECO:0007829|PDB:2LRU"
FT   STRAND          521..527
FT                   /evidence="ECO:0007829|PDB:2LRU"
FT   TURN            528..530
FT                   /evidence="ECO:0007829|PDB:2LRU"
FT   HELIX           533..542
FT                   /evidence="ECO:0007829|PDB:2LRU"
FT   HELIX           548..550
FT                   /evidence="ECO:0007829|PDB:2LRU"
FT   HELIX           551..568
FT                   /evidence="ECO:0007829|PDB:2LRU"
SQ   SEQUENCE   2126 AA;  225112 MW;  89AC72F9CC8B07DF CRC64;
     MSDGTAEKQS GTPGFLSPPA PVPKNGSSSD SSVGEKLGAA VADSGIGRTE EYRRRRHTMD
     KDSRGAAATT TPTEHRFFRR SVICDSNATA LELPGLPLSI PQPSVPAVVP QSAPPEPHRE
     ETLTATVASQ VSQQPSAAAS PGEQAVVGSA TATVPSSTSK DRPVSQPSLV GSKEEPPPSR
     SGSGSGGASA KEPQEERNQQ QDDIEELETK AVGMSNDGRF LKFDIEIGRG SFKTVYKGLD
     TETTVEVAWC ELQDRKLTKS ERQRFKEEAE MLKGLQHPNI VRFYDSWEST VKGKKCIVLV
     TELMTSGTLK TYLKRFKVMK IKVLRSWCRQ ILKGLQFLHT RTPPIIHRDL KCDNIFITGP
     TGSVKIGDLG LATLKRASFA KSVIGTPEFM APEMYEEKYD ESVDVYAFGM CMLEMATSEY
     PYSECQNAAQ IYRRVTSGVK PASFDKVAIP EVKEIIEGCI RQNKDERYSI KDLLNHAFFQ
     EETGVRVELA EEDDGEKIAI KLWLRIEDIK KLKGKYKDNE AIEFSFDLER DVPEDVAQEM
     VESGYVCEGD HKTMAKAIKD RVSLIKRKRE QRQLVREEQE KRKQEESSFK QQNEQQASVS
     QAGIQPLSVA STGIPTAPTT SASVSTQVEP EEPEADQHQQ LQYQQPSISV LSDGTVDSGQ
     GSSVFTESRV SSQQTVSYGS QHEQAHSIGT APGHTVSSIQ AQSQPHGVYP PSSMAQGQNQ
     GQPSSSLAGV LSSQPVQHPQ QQGIQPTVPP QQAVQYSLPQ AASSSEGTVQ PVSQPQVSAG
     TQSSTQGVSQ AAPPEQTPIT QSQPTQPVPL VSSVDSAHSD VASGMSDGNE NAPSSSGRHE
     GRTTKRHYRK SVRSRSRHEK TSRPKLRILN VSNKGDRVVE CQLETHNRKM VTFKFDLDGD
     NPEEIATIMV NNDFILAIER ESFVAQVREI IEKADEMLSE DVSVEPEGDQ GLESLQGKDD
     YGFPGSQKLE GEFKQPIAVS SMPQQIGVPT SSLTQVVHSA GRRFIVSPVP ESRLRESKIF
     TSEIPDPVAA STSQGPGMNL SHSASSLSLQ QAFSELKHGQ MTEGPNTAPP NFNHPGPTFS
     PFLTSIAGVQ TVAASTPSVS VPITSSPLND ISTSVMQSEG ALPTDKGIGG VTTSTGVVAS
     GGLTTLSVSE TPTLSSAVSS STAPAVVTVS TTSQPVQAST SGSIASSTGS FPSGTFSTTT
     GTTVSSVAVP NAKPPTVLLQ QVAGNTAGVA IVTSVSTTTP FPAMASQPSL PLGSSTSAPT
     LAETVVVSAH SLDKASHSST AGLGLSFCAP SSSSSSGTAV SSSVSQPGIV HPLVISSAIA
     STPVLPQPAV PTSTPLLPQV PNIPPLVQPV ANVPAVQQTL IHSQPQPALL PNQPHTHCPE
     MDADTQSKAP GIDDIKTLEE KLRSLFSEHS SSGTQHASVS LETPLVVETV TPGIPTTAVA
     PSKLMTSTTS TCLPPTNLPL GTAGMPVMPV GTPGQVSTPG THASAPASTA TGAKPGTTPP
     KPSLTKTVVP PVGTELSAGT VPCEQLPPFP GPSLIQTQQP LEDLDAQLRR TLSPETIPVT
     PAVGPLSTMS STAVTEAGSQ PQKDGTEVHV TASSSGAGVV KMGRFQVSVT MDDAQKERKN
     RSEDTKSVHF ESSTSESSVL SSSSPESTLV KPEPNGITVS GISLDVPDST HRTPTPEAKS
     ETGQPTKVGR FQVTTTANKV GRFSVSRTED KVTELKKEGP VTSPFRDSEQ TVIPAAIPKK
     EKPELAEPSH LNGPSSDLEA AFLSRGGEDG SGSPHSPPHL CSKSLPIQTL SQSLSNSFNS
     SYMSSDNESD IEDEDLRLEL RRLREKHLKE IQDLQSRQKH EIESLYTKLG KVPPAVIIPP
     AAPLSGRRRR PTKSKGSKSS RSSSLGNKSP QLSGNLSGQS GTSVLNPQQT LHPPGNTPET
     GHNQLLQPLK PSPSSDNLYS AFTSDGAISV PSLSAPGQGT SSTNTVGGTV SSQAAQAQPP
     AMTSSRKGTF TDDLHKLVDN WARDAMNLSG RRGSKGHMNY EGPGMARKFS APGQLCISMT
     SNMGGSTPIS AASATSLGHF TKSMCPPQQY GFPAAPFGTQ WSGTGGPAPQ PLGQFQPVGT
     TSLQNFNISN LQKSISNPPG SNLRTT
//
